OBBI is supported by France 2030, the national investment programme aimed at accelerating innovation in key sectors, including health and biotherapies. Through this funding, OBBI was designated as an Integrateur Biothérapie–Bioproduction, enabling the platform to develop its organoid and extracellular vesicle bioproduction capacities. France 2030 support allows OBBI to invest in cutting-edge equipment, quality control processes, and collaborative projects to advance next-generation biotherapies.
This work received support from the State managed by the French National Research Agency (Agence Nationale de la Recherche) under the France 2030 program, reference ANR-22-AIBB-007